Jessica Power, B.Sc.(Pharm.), ACPR Experiential Education Facilitator and Clinical Pharmacist, Victoria General Hospital This presentation will be an introduction to EEF role, a discussion of novel precepting models, as well as strategies to face inherent challenges. We will look at OEE changes to rotations including
This presentation will be an introduction to EEF role, a discussion of novel precepting models, as well as strategies to face inherent challenges. We will look at OEE changes to rotations including description of the new IPPE II PHRM 272 rotation activities and work through three difficult student situations.
Disease Stephanie Tarasoff, BScPharm, ACPR Clinical Pharmacist, Royal Jubilee Hospital
This presentation will be a review of two complex aspects of chronic kidney disease: bone mineral metabolism and anemia of chronic kidney disease. Pathophysiology, pharmacotherapy, monitoring parameters, and clinical pearls will be reviewed.
Arden Barry, BSc, BSc(Pharm), PharmD, ACPR Clinical Pharmacy and Research Specialist, Lower Mainland Pharmacy Services; Assistant Professor (Partner), Faculty of Pharmaceutical Sciences, University of British Columbia; Associate Member, Department of Family Practice, Faculty of Medicine, University of British Columbia
The treatment of dyslipidemia is controversial despite a plethora of available published evidence. This has led to the development of multiple dyslipidemia guidelines— while these documents differ with respect philosophy and complexity, they are more similar than they are different. This presentation aims to explore three recently published dyslipidemia guidelines with the goal of deriving a few pragmatic considerations that participants can apply in practice.
Amy Nunley, BScPh, ACPR
Review of medications used to manage NSTEACS.
Describe at least 4 risk factors for NSTE-ACS
List at least 3 medications that have mortality benefit after NSTE-ACS
List target doses and monitoring parameters for each of:
- Antiplatelets (Acetylsalicylic Acid [ASA], clopidogrel, ticagrelor)
Julie Gagnon, Pharmacist – Mat/Child, UHNBC Prince George
Review of the RSV program in Northern Health and Neonatal Hyperbilirubinemia.
RSV program in NH – Objectives:
Identify differences in seasonal eligibility across British Columbia
Determine eligibility of infants for RSV prophylaxis based on current program standards
Understand process for both initial dosing and subsequent administration
Answer common questions related to administration including dosing and eligibility
Neonatal Hyperbilirubinemia – Objectives:
Review bilirubin metabolism
Potential consequences of high bilirubin
Risk factors associated with prematurity
Evaluating drug safety and alternatives
Dr. Anurag Markanday, MD, FRCPC, FACP
Consultant physician in Infectious Diseases and Head, Department of Medicine, Abbotsford Regional Hospital and Cancer Centre
Review of the diagnosis and treatment of nosocomial pneumonia.
Dr. Arden Barry, BSc, BScPharm, PharmD, ACPR
Clinical Pharmacy and Research Specialist, Lower Mainland Pharmacy Services
Assistant Professor (Partner), Faculty of Pharmaceutical Sciences, University of British Columbia
Identify recently published guidelines for the treatment of dyslipidemia
Review key clinical trials in the management of dyslipidemia published since 2012
Review the key recommendaEons relevant to pharmacists from the (to be published) updated Canadian Cardiovascular Society guidelines for the management of dyslipidemia.